Ep. 3 Hartaj Singh Shares His Optimism for Early-Stage Biotech Companies From a Public Market Perspective

Spark Time!
27/02/2024 40 min Temporada 1 Episodio 3
Ep. 3 Hartaj Singh Shares His Optimism for Early-Stage Biotech Companies From a Public Market Perspective

Listen "Ep. 3 Hartaj Singh Shares His Optimism for Early-Stage Biotech Companies From a Public Market Perspective"

Descargar episodio Ver en sitio original

Episode Synopsis

Join us as we discuss with Hartaj Singh the essential elements of messaging in the public biotech arena, and his advice to management teams of early-stage companies.

More episodes of the podcast Spark Time!

Ep. 30 The Tiny Cargo Company's Milk Exosomes Could Shape the Future of Oral GLP-1 Delivery 09/10/2025
Ep. 29 Christian Kersten & Marte Cameron: From Serendipitous Discovery to a New Era in Chronic Pain Treatment 03/09/2025
Ep. 28 Aneil Mallavarapu on Building and Monetizing TechBio Platforms, Storytelling and Why Diagnostics Won't Save a System Designed to Fail 26/07/2025
Ep. 27 Burn the CRO Playbook: Ardian Latifi on Building a Sponsor-First Model 29/06/2025
Ep. 26 The Australian Advantage; How Global Biotechs Are Accelerating R&D with Agilex Biolabs 05/06/2025
Ep. 25 Javier Tordable Saw Biotech's Blind Spot. Then Built a Company to Fix It. 02/05/2025
Ep. 24 AI vs. Clinical Trial Chaos: Maree Beare Isn't Waiting Around 21/04/2025
Ep. 23 Jason Foster on Scaling Indivior, Leading Ori Biotech, and Solving the Real-World Bottlenecks Holding Back Cell and Gene Therapy 06/04/2025
Ep. 22 Audrey Greenberg on Strategically Enabling Cell & Gene Therapy 09/03/2025
Ep. 21 Emily Fang on Authentically Understanding a Global Audience 20/02/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA